Transcat, Inc. is a provider of accredited calibration and laboratory instrument services, and a value-added distributor of professional grade test, measurement, and control instrumentation. The company operates through two segments, Service and Distribution, and focuses on providing services and products to highly regulated industries, particularly the life science industry, which includes pharmaceutical, biotechnology, and medical device businesses.
CEO: Jaime A. Irick. Company website
Transcat, Inc. (TRNS) trades at $86.00, up 0.84% on the day, as of Sep 20, 2026 15:01 UTC.
Transcat, Inc. has a market capitalisation of $804.94M, calculated from the live TRNS share price and shares outstanding.
TRNS trades at a trailing P/E of 232.43, from earnings per share of $0.37 over the last twelve months.
Transcat, Inc. generated revenue of $348.40M over the trailing twelve months, which puts the stock at 2.31 times sales.
TRNS has traded between $50.23 and $100.00 over the past 52 weeks, and the last price is 14.0% below that high.
Yes. Transcat, Inc. keeps 0.99% of revenue as net income over the trailing twelve months.
Wall Street analysts rate TRNS Buy, with an average price target of $123.60, 43.7% above the current price.
Transcat, Inc. is classified under the Industrials sector and the Specialty Business Services industry, and is domiciled in US.
Jaime A. Irick is the chief executive of Transcat, Inc., which employs 1,413 people.
QFI Terminal shows TRNS with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open TRNS in Terminal See plans